Jenna Besley1, Juanita Pappalardo2, Graham A Lee3, Lawrence W Hirst4, Stephen J Vincent5. 1. Department of Ophthalmology, City Eye Centre, Brisbane, Australia. 2. Department of Ophthalmology, City Eye Centre, Brisbane, Australia; Department of Ophthalmology, University of Queensland, Brisbane, Australia. 3. Department of Ophthalmology, City Eye Centre, Brisbane, Australia; Department of Ophthalmology, University of Queensland, Brisbane, Australia; Department of Ophthalmology, Royal Brisbane Hospital, Brisbane, Australia. Electronic address: eye@cityeye.com.au. 4. Department of Ophthalmology, University of Queensland, Brisbane, Australia; Department of Ophthalmology, The Australian Pterygium Centre, Brisbane, Australia; Department of Ophthalmology, Queensland Eye Institute, Brisbane, Australia. 5. School of Optometry and Vision Science, Queensland University of Technology, Kelvin Grove, Australia.
Abstract
PURPOSE: To determine the rate of recurrence and associated risk factors after the use of mitomycin C (MMC), interferon alpha-2b, or both for management of noninvasive ocular surface squamous neoplasia (OSSN). DESIGN: Retrospective, noncomparative, interventional case series. METHODS: Clinical practice setting of 135 patients treated consecutively with topical MMC (0.4 mg/mL), interferon alpha-2b (1 million units/mL), or both for OSSN observed for clinical recurrence. RESULTS: Clinical recurrences were diagnosed in 19 (14.1%) of 135 eyes after topical treatment. The mean time to recurrence was 17.2 months (range, 4 to 61 months), with 14 eyes (73.7%) recurring within a 2-year period. There was no greater risk of recurrence identified for variables including lesion size, lesion location, gender, age, treatment type, or treatment duration. Post hoc log-rank pairwise comparisons revealed that lesions initially treated using surgery alone had significantly reduced time to recurrence (21.1 ± 5.6 months) compared with previous topical treatment with MMC (with or without surgery; 29.6 ± 4.7 months; P = .04) and primary OSSN (23.2 ± 1.8 months; P = .09). CONCLUSIONS: Topical MMC and interferon alpha-2b are an effective treatment method for a wide range of noninvasive OSSNs. Topical therapy avoids the morbidity of excisional surgery with equivalent or reduced recurrence rates and should be considered as primary therapy.
PURPOSE: To determine the rate of recurrence and associated risk factors after the use of mitomycin C (MMC), interferon alpha-2b, or both for management of noninvasive ocular surface squamous neoplasia (OSSN). DESIGN: Retrospective, noncomparative, interventional case series. METHODS: Clinical practice setting of 135 patients treated consecutively with topical MMC (0.4 mg/mL), interferon alpha-2b (1 million units/mL), or both for OSSN observed for clinical recurrence. RESULTS: Clinical recurrences were diagnosed in 19 (14.1%) of 135 eyes after topical treatment. The mean time to recurrence was 17.2 months (range, 4 to 61 months), with 14 eyes (73.7%) recurring within a 2-year period. There was no greater risk of recurrence identified for variables including lesion size, lesion location, gender, age, treatment type, or treatment duration. Post hoc log-rank pairwise comparisons revealed that lesions initially treated using surgery alone had significantly reduced time to recurrence (21.1 ± 5.6 months) compared with previous topical treatment with MMC (with or without surgery; 29.6 ± 4.7 months; P = .04) and primary OSSN (23.2 ± 1.8 months; P = .09). CONCLUSIONS: Topical MMC and interferon alpha-2b are an effective treatment method for a wide range of noninvasive OSSNs. Topical therapy avoids the morbidity of excisional surgery with equivalent or reduced recurrence rates and should be considered as primary therapy.
Authors: Andrew N Siedlecki; Stephanie Tapp; Anna N A Tosteson; Robin J Larson; Carol L Karp; Thomas Lietman; Michael E Zegans Journal: Cornea Date: 2016-05 Impact factor: 2.651
Authors: Madhura G Joag; Adam Sise; Juan Carlos Murillo; Ibrahim Osama Sayed-Ahmed; James R Wong; Carolina Mercado; Anat Galor; Carol L Karp Journal: Ophthalmology Date: 2016-03-27 Impact factor: 12.079
Authors: Stephen Gichuhi; Ephantus Macharia; Joy Kabiru; Alain M'bongo Zindamoyen; Hilary Rono; Ernest Ollando; Leonard Wanyonyi; Joseph Wachira; Rhoda Munene; Timothy Onyuma; Mandeep S Sagoo; Helen A Weiss; Matthew J Burton Journal: JAMA Ophthalmol Date: 2015-11 Impact factor: 7.389